NICE has assessed 2 point-of-care coagulometers to help the NHS decide whether to use these products. They are called CoaguChek XS and InRatio2 PT/INR. The INRatio2 PT/INR was withdrawn from the market in October 2016 and is not currently available.

Coagulometers monitor blood clotting in people taking long-term anti-blood clotting drugs (such as warfarin) to reduce their risk of blood clots. These tests allow people taking anti-blood clotting drugs to monitor blood clotting themselves. They can then change their dose in agreement with their health professional.

CoaguChek XS is recommended for use by people taking long-term anti-blood clotting therapy who have atrial fibrillation or heart valve disease, if they prefer and are able to effectively use this type of monitoring.

People (and their carers) who will be using a coagulometer should be given training, and their doctor should regularly assess self-monitoring.

Is this guidance up to date?

We reviewed the evidence in November 2017. The recommendations have been updated because the InRatio2 PT/INR is no longer available. We found nothing else that affects the recommendations in this guidance.

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.

Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

  • National Institute for Health and Care Excellence (NICE)